Through a randomized, double-blind, placebo-controlled clinical trial, researchers at Brigham and Women's Hospital discovered that the insomnia drug suvorexant developed by Merck & Co., was safe and effective, improving insomnia and night sweats in peri- and postmenopausal women.
New study reveals risk factors of developing type 2 diabetes that are not genetic such as insomnia, sleep quality, and caffeine consumption. These specific risk factors can help create new preventive strategies of developing T2D as it is increasingly seen in obese children.